Effects of ω-3 PUFAs Supplementation on Myocardial Function and Oxidative Stress Markers in Typical Rett Syndrome

Table 1

Phenotypical severity, biometrics, bone densitometry estimates, and 25-hydroxy vitamin D serum levels were comparable between the 𝜔-3 PUFAs-supplemented and the untreated Rett patients subgroups.

Variables	Rett syndrome population		𝑃 value
	𝜔-3 PUFAs supplemented (𝑛=33)	Untreated (𝑛=33)
Age (years)	13.0±8.6	12.4±9.3	0.7864
Clinical severity score (CSS)	26.2±11.2	26.0±11.1	0.9421
Height (RTT 𝑧-score for age)^1	0.078±0.924	−0.025±1.47	0.7344
Body weight (RTT 𝑧-score for age)^1	−0.027±1.026	−0.02±1.2	0.9798
Body mass index (RTT 𝑧-score for age)^1	−0.30±1.55	−0.40±1.6	0.7973
Head circumference (RTT 𝑧-score for age)^1	−0.07±1.23	0.01±0.99	0.7719
Heart rate (bpm)	91±17	93±15	0.6141
Systolic blood pressure (mmHg)	107.8±8.2	107.1±9.3	0.7468
Diastolic blood pressure (mmHg)	70.2±11.6	69.9±8.9	0.9065
Bone densitometry
AD-SoS (𝑧-score for age)	−2.86±1.75	−2.74±1.81	0.7951
BTT (𝑧-score for age)	−1.87±1.93	−1.9±1.85	0.9488
Serum 25-OH vitamin D (ng/mL)	45.1±26.1	46.5±25.8	0.8307

¹𝑧-scores are referred to validated Rett syndrome-specific growth charts [27].
AD-SoS: amplitude-dependent speed of sound; BTT: bone transmission time.
AD-SoS and BTT were evaluated by quantitative ultrasound (QUS) of the distal end of the first phalanx diaphysis of the last four fingers of the hand.